![](https://www.pymnts.com/wp-content/uploads/2021/11/shutterstock_1642618876-e1606213836709.jpg)
Merck has received antitrust clearance from the competition authorities in Germany and Austria to tender an offer for the acquisition of clinical-stage biopharmaceutical firm Acceleron Pharma.
The latest move follows a definitive agreement signed by the company for the acquisition last month.
Related: Merck To Buy Acceleron For US$11.5B
Merck, through its subsidiary, commenced a cash tender offer to acquire Acceleron’s all outstanding shares, for US$180 per share, as announced on October 12 of this year.
Merck stated, “As previously announced on 29 October 2021, the tender offer will expire at 5:00 p.m., Eastern Time, on 18 November 2021, unless further extended in accordance with the merger agreement and the applicable rules and regulations of the SEC.”
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Geradin Partners Expands Paris Office with Key Hire
Aug 30, 2024 by
CPI
Judge Accuses Google of ‘Clear Abuse’ in Antitrust Case Over Deleted Employee Chats
Aug 29, 2024 by
CPI
Hong Kong Cleaning Company Employee Charged in Historic Antitrust Investigation Case
Aug 29, 2024 by
CPI
Inside the Yelp Suit: Allegations of Google’s Abuse of Search Power
Aug 29, 2024 by
CPI
AI Safety Bill Clears Hurdle in California, Heads to Governor’s Desk
Aug 29, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – State Attorneys General
Aug 22, 2024 by
CPI
CPI Talks… …With Attorney General Phil Weiser
Aug 22, 2024 by
CPI
The Bipartisan Miracle of State Antitrust Enforcement
Aug 22, 2024 by
Gwendolyn J. Lindsay Cooley
Recent Developments in State Antitrust Enforcement: Agriculture and Food Markets
Aug 22, 2024 by
Elizabeth R. Odette
State Attorneys General: Stewards of Consumer Health and Welfare
Aug 22, 2024 by
Brooke Howlett Lovrovich